Thozalinone (chemical code name CL-39808) is a synthetic psychostimulant that has been investigated as an antidepressant and potential weight‑loss medication in some European research programs.[CIT-1] It is not approved by the U.S. Food and Drug Administration (FDA) and is not available as a prescription medication in the United States as of 2026.(Source)

Thozalinone appears to increase the release of two key neurotransmitters in the brain: dopamine and norepinephrine.(Source) These chemicals play major roles in mood, motivation, attention, and the body’s stress response.

Dopamine is involved in reward, pleasure, and movement. Higher dopamine levels in certain brain regions can temporarily elevate mood and energy.(Source) Norepinephrine helps regulate alertness, focus, and the “fight‑or‑flight” response, and can increase heart rate and blood pressure.(Source) When dopamine and norepinephrine are released together, the overall effect can resemble that of other stimulants, such as amphetamine‑based medications used to treat ADHD.(Source)

Thozalinone was first developed in the 1960s and 1970s as a potential antidepressant, and early animal and small human studies suggested stimulant and mood‑elevating effects.(Source) However, compared with modern antidepressants like SSRIs and SNRIs, thozalinone has been studied far less, and there is limited high‑quality, long‑term clinical data in humans.(Source)

Because thozalinone acts on dopamine and norepinephrine—systems that are also involved in addiction and reward—there is a theoretical risk that it could be misused, especially at higher‑than‑therapeutic doses or outside medical supervision.(Source) At the same time, the true abuse potential in real‑world settings is not well defined due to the lack of large, modern clinical trials.

Thozalinone is often described in the scientific literature as an “excitant” or psychostimulant rather than a classic antidepressant.(Source) In the United States, most commonly prescribed antidepressants—such as SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin‑norepinephrine reuptake inhibitors)—work mainly by gradually increasing serotonin and/or norepinephrine levels over time, without producing a strong stimulant “high.”(Source)

By contrast, thozalinone has pharmacologic properties more similar to stimulant medications. Early animal studies found that thozalinone produced behavioral stimulation and had some similarities to amphetamine and the tricyclic antidepressant imipramine, but with a different toxicity profile.(Source)

Key differences highlighted in early research include:(Source)

• Stimulant profile: Thozalinone produced increased activity and wakefulness in animal models, consistent with stimulant effects.
• Lower acute toxicity in animals: In some studies, thozalinone appeared less toxic than amphetamine in mice, with a wider margin of safety at tested doses.(Source)
• Anorexigenic (appetite‑suppressing) effect: Thozalinone reduced food intake in animals, and this effect was sometimes stronger and longer‑lasting than that of amphetamine, which led to interest in its potential as a weight‑loss agent.(Source)

Some early work suggested that tolerance to thozalinone’s stimulant effects might develop more slowly than with other stimulants, but these findings were based on limited preclinical data and have not been confirmed in large human studies.(Source)

Unlike many traditional antidepressants, thozalinone appears to have relatively modest direct effects on the cardiovascular system in animal models, though any stimulant that increases norepinephrine can potentially raise heart rate and blood pressure.(Source) Long‑term cardiovascular safety in humans has not been established.

Because of these uncertainties, thozalinone has not become a standard antidepressant in Europe or elsewhere, and it remains largely a research compound rather than a widely used medication.(Source)

Thozalinone is sometimes discussed alongside novel psychoactive substances (NPS) because it is a lesser‑known stimulant with limited clinical use and a pharmacologic profile that could attract people seeking new or “legal high” options.(Source)

What are novel psychoactive substances?

Novel psychoactive substances are synthetic drugs designed to mimic the effects of controlled substances like cocaine, MDMA, or amphetamines, while initially avoiding existing drug laws by altering their chemical structure.(Source) These substances are often sold online or in informal markets as “research chemicals,” “bath salts,” or “legal highs.”

Producers—frequently operating in loosely regulated or clandestine laboratories—may make small changes to the molecular structure of known drugs to create new compounds that are not yet specifically listed as illegal.(Source) In response, many countries, including the United States, have adopted broader “analogue” or class‑based scheduling laws to control groups of related substances rather than one chemical at a time.(Source)

NPS can be especially dangerous because:

• Potency and composition are unpredictable. The same product name can contain different chemicals from batch to batch.(Source)
• Doses are not standardized. Users may unknowingly take far more than intended.
• Toxicity is often unknown. Many NPS have little or no human safety data before they appear on the market.(Source)

During the early 2010s, synthetic cathinones—often sold as “bath salts”—caused a wave of emergency department visits and media reports in the United States and Europe.(Source) These drugs produced intense euphoria and stimulation but were also linked to severe agitation, paranoia, psychosis, hyperthermia, and cardiovascular collapse.(Source)

Research suggests that adolescents, young adults, and people with a history of substance use disorders are more likely to experiment with NPS, often underestimating the risks because the products are marketed as “legal” or “research chemicals.”(Source)

While thozalinone itself is not a mainstream NPS, its stimulant properties and limited regulatory status in some regions raise concerns that related compounds—or misrepresented products using the name “thozalinone”—could appear in online markets. Any substance purchased outside a regulated medical or pharmacy system carries significant risk of contamination, mislabeling, and overdose.(Source)

Because thozalinone acts on dopamine and norepinephrine, it has at least a theoretical potential for misuse and dependence, similar to other stimulants.(Source) However, there is very limited modern human research specifically examining thozalinone’s abuse liability, and it is not widely prescribed or available in most countries.(Source)

Some early pharmacologic descriptions suggested that thozalinone’s onset of action might be slower and its effects more sustained than those of classic “rush‑producing” stimulants like cocaine.(Source) In general, drugs that enter the brain rapidly and cause a sudden spike in dopamine are more likely to be addictive than those that produce a gradual increase.(Source)

That said, any stimulant that enhances dopamine signaling can be misused, especially if taken in higher doses, more frequently than prescribed, or by routes that increase how quickly the drug reaches the brain (such as snorting or injecting crushed tablets).(Source)

Potential risks of thozalinone misuse may include:

• Using the drug without a prescription or outside medical supervision
• Taking larger or more frequent doses to enhance mood, focus, or weight loss
• Combining it with other stimulants, alcohol, or illicit drugs
• Continuing use despite health, relationship, or legal problems

Because thozalinone is not approved in the U.S. and is rarely used clinically elsewhere, there is not enough evidence to clearly rank its addictive potential compared with other stimulants. From a safety standpoint, it is best to assume that any non‑prescribed stimulant with dopaminergic effects can lead to psychological dependence, withdrawal symptoms, and serious health consequences if misused.(Source)

There are no large, modern clinical studies describing a specific “thozalinone misuse syndrome.” However, misuse of thozalinone would be expected to resemble misuse of other stimulants and novel psychoactive stimulants.(Source)

If you or someone you care about were misusing a stimulant like thozalinone, you might notice:

• Changes in appetite and weight: Stomach pain, nausea, or significant loss of appetite, which can lead to weight loss and fatigue.(Source)
• Mood and behavior changes: Irritability, anxiety, agitation, or sudden mood swings; in some cases, paranoia or suspiciousness.(Source)
• Cardiovascular symptoms: Rapid heart rate (tachycardia), increased blood pressure, palpitations, or chest discomfort.(Source)
• Increased energy and activity: Restlessness, inability to sit still, excessive talking, or staying awake for long periods.(Source)
• Panic or psychotic symptoms at high doses: Panic attacks, hallucinations, or delusional thinking, especially with heavy or prolonged use.(Source)
• Physical complaints: Dizziness, dry mouth, headaches, or feeling overheated.

In severe cases, high‑dose stimulant misuse can lead to dangerous complications such as heart rhythm disturbances, seizures, stroke, or hyperthermia (dangerously high body temperature).(Source)

Anyone showing signs of stimulant or NPS misuse should seek professional help as soon as possible. Attempting to stop suddenly without support can lead to withdrawal symptoms such as fatigue, depression, increased appetite, and intense cravings, which may increase the risk of relapse or self‑harm.(Source)

A medically supervised detoxification program can monitor vital signs, manage withdrawal symptoms, and address co‑occurring mental health concerns in a safer, more controlled environment than trying to quit alone.(Source)

Because thozalinone is not widely used or approved, there is no standardized, thozalinone‑specific treatment protocol. However, clinicians can draw on decades of experience treating stimulant and NPS use disorders, which share many clinical features.(Source)

Professionals now use the term substance use disorder (SUD) to describe patterns of misuse, dependence, and addiction, recognizing that these are interconnected aspects of the same condition rather than separate stages.(Source)

Key components of treatment for stimulant or NPS use disorders may include:

1. Comprehensive assessment

• Evaluation of substance use history, mental health, medical conditions, and social supports.
• Screening for co‑occurring disorders such as depression, anxiety, PTSD, or ADHD, which are common among people with stimulant use disorders.(Source)

2. Medically supervised detoxification (when needed)

• Monitoring for cardiovascular complications, severe agitation, or suicidal thoughts.
• Supportive care for withdrawal symptoms such as fatigue, low mood, and sleep disturbances.(Source)

3. Evidence‑based behavioral therapies

• Cognitive behavioral therapy (CBT) to help identify triggers, change unhelpful thought patterns, and build coping skills.(Source)
• Contingency management, which uses structured rewards to reinforce abstinence and treatment engagement.(Source)
• Motivational interviewing to strengthen a person’s own reasons for change.

4. Treatment of co‑occurring mental health conditions

• Appropriate use of non‑addictive medications (such as SSRIs or SNRIs) when indicated for depression or anxiety.(Source)
• Integrated care that addresses both substance use and mental health at the same time, which is associated with better outcomes.(Source)

5. Supportive environment and continuing care

• Residential or intensive outpatient programs can provide structure, peer support, and a safe space to focus on recovery.
• Ongoing aftercare—such as outpatient counseling, peer support groups, and relapse‑prevention planning—helps maintain progress over the long term.(Source)

Trying to detox from stimulants or NPS alone can be overwhelming and, in some cases, medically risky. Working with a licensed addiction treatment program gives individuals access to medical monitoring, mental health support, and evidence‑based therapies that significantly improve the chances of sustained recovery.(Source)

Because thozalinone is not approved for use in the United States and has limited clinical availability elsewhere, confirmed cases of thozalinone misuse are rare compared with more common stimulants like prescription amphetamines, methamphetamine, or cocaine.[CIT-48] However, as global markets for research chemicals and NPS continue to evolve, it is important for clinicians, patients, and families to be aware of emerging substances and their potential risks.(Source)

If you or someone you know is taking a stimulant—whether prescribed, purchased online, or obtained from friends—and is showing signs of misuse, dependence, or addiction, professional help is available. Warning signs can include taking more than prescribed, using the drug to cope with stress or emotions, experiencing cravings, or continuing use despite health, work, or relationship problems.(Source)

Attempting to stop stimulant or NPS use without medical support can lead to intense fatigue, depression, sleep changes, and cravings, which may increase the risk of relapse or self‑harm.(Source) An evidence‑based rehabilitation program offers a safer, more supportive path by combining medical supervision, counseling, and behavioral therapies tailored to each person’s needs.

At Cardinal Recovery, we provide compassionate, research‑informed care for people struggling with substance use and co‑occurring mental health conditions. Our team focuses on the whole person—mental, physical, and behavioral health—to help individuals build a strong foundation for long‑term recovery.

If you’re ready to explore treatment options for stimulant or NPS misuse, or you simply have questions about how to help a loved one, contact Cardinal Recovery today to learn more about our programs and how we can support your next steps.